56 related articles for article (PubMed ID: 9655875)
1. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs.
Smit JW; Weert B; Schinkel AH; Meijer DK
J Pharmacol Exp Ther; 1998 Jul; 286(1):321-7. PubMed ID: 9655875
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
3. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
Smit JW; Schinkel AH; Müller M; Weert B; Meijer DK
Hepatology; 1998 Apr; 27(4):1056-63. PubMed ID: 9537446
[TBL] [Abstract][Full Text] [Related]
4. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level.
Smit JW; Duin E; Steen H; Oosting R; Roggeveld J; Meijer DK
Br J Pharmacol; 1998 Feb; 123(3):361-70. PubMed ID: 9504375
[TBL] [Abstract][Full Text] [Related]
5. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).
Tanigawara Y; Okamura N; Hirai M; Yasuhara M; Ueda K; Kioka N; Komano T; Hori R
J Pharmacol Exp Ther; 1992 Nov; 263(2):840-5. PubMed ID: 1359120
[TBL] [Abstract][Full Text] [Related]
6. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs.
Leung S; Bendayan R
Can J Physiol Pharmacol; 1999 Aug; 77(8):625-30. PubMed ID: 10543726
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
9. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
10. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
11. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Ito T; Yano I; Tanaka K; Inui KI
J Pharmacol Exp Ther; 1997 Aug; 282(2):955-60. PubMed ID: 9262363
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein.
Woodahl EL; Yang Z; Bui T; Shen DD; Ho RJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1199-207. PubMed ID: 15100388
[TBL] [Abstract][Full Text] [Related]
13. Effects of P-glycoprotein inhibitors on transepithelial transport of cadmium in cultured renal epithelial cells, LLC-PK1 and LLC-GA5-COL 150.
Kimura O; Endo T; Hotta Y; Sakata M
Toxicology; 2005 Mar; 208(1):123-32. PubMed ID: 15664439
[TBL] [Abstract][Full Text] [Related]
14. Interaction of imatinib mesilate with human P-glycoprotein.
Hamada A; Miyano H; Watanabe H; Saito H
J Pharmacol Exp Ther; 2003 Nov; 307(2):824-8. PubMed ID: 12975485
[TBL] [Abstract][Full Text] [Related]
15. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
16. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein.
Iwaki K; Sakaeda T; Kakumoto M; Nakamura T; Komoto C; Okamura N; Nishiguchi K; Shiraki T; Horinouchi M; Okumura K
J Pharm Pharmacol; 2006 Dec; 58(12):1617-22. PubMed ID: 17331325
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein expression in human retinal pigment epithelium cell lines.
Constable PA; Lawrenson JG; Dolman DE; Arden GB; Abbott NJ
Exp Eye Res; 2006 Jul; 83(1):24-30. PubMed ID: 16530756
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers.
Endter S; Becker U; Daum N; Huwer H; Lehr CM; Gumbleton M; Ehrhardt C
Cell Tissue Res; 2007 Apr; 328(1):77-84. PubMed ID: 17165089
[TBL] [Abstract][Full Text] [Related]
20. Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein.
Ji Y; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):640-7. PubMed ID: 16002050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
